Search Results: Intellectual Property Litigation

Valeant Pharmaceuticals et al v. Actavis Laboratories

Actavis markets a generic version of the brand-name medication Uceris. The brand-name company and the owner of its IP have sued for infringement of formulation patents that allegedly cover Uceris. The district court construed the patent claims, and under that construction Actavis’s product does not infringe. Goodwin argues in this…

Read More

GlaxoSmithKline LLC and SmithKline Beecham (Cork) Limited v. Teva Pharmaceuticals USA, Inc.

In a closely watched patent case that is especially important to pharmaceutical patent litigation, a divided panel of the Federal Circuit upheld a verdict against Teva Pharmaceuticals USA, Inc. for $235 million for inducing infringement of a method patent. The panel upheld the inducement finding even though Teva had used…

Read More

Bayer v. Watson Laboratories

In this case, Goodwin attorneys persuaded the Federal Circuit to reverse a district court decision and find a patent relating to an orally disintegrating tablet formulation of vardenafil (an erectile dysfunction treatment branded as Staxyn) invalid for obviousness.  The unanimous Federal Circuit decision held that the district court’s purported credibility…

Read More

Massachusetts Institute of Technology v. Shire

Goodwin represented MIT and the Children’s Medical Center Corporation in a dispute against Shire Pharmaceuticals, Inc. and Shire Regenerative Medicine, Inc. (collectively, “Shire”) for infringement of two patents concerning the production of a three-dimensional scaffolding that would allow pre-grown cells to produce organ tissue in a patient. Goodwin prevailed in…

Read More